Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company, said Tuesday that its FT819 treatment exhibited enhanced tumor clearance compared...
Fate Therapeutics' (FATE) shares were up nearly 45% in late-afternoon trading after the company said that new preclinical data for FT596, its multi-antigen...
Fate Therapeutics (FATE) has an average rating among analysts of buy, with an average price target of $25. Price: 19.08, Change: +5.41, Percent Change:...
Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $25. Price: 13.67, Change: +0.10, Percent Change: +0.74...
| Address | 3535 General Atomics Court San Diego, California 92121 |
| Phone | +1.858.875.1800 |
| Number of Employees | 104 |
| Recent SEC Filing | 11/14/2019 8-K |
| President, Chief Executive Officer & Director | J. Scott Wolchko |
| Chief Scientific Officer | Daniel D. Shoemaker |
| Vice President-Clinical Development | Yu Waye Chu |
| Senior Vice President-Corporate Development | Jim Beitel |
| Price Open | $19.04 |
| Previous Close | $18.68 |
| 52 Week Range | $11.00 - 22.82 |
| Market Capitalization | $1.4 B |
| Shares Outstanding | 75.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/03/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.31 |
| Beta vs. S&P 500 | N/A |
| Revenue | $4.7 M |
| Net Profit Margin | -900.24% |
| Return on Equity | -48.94% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
